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EDITORIAL
Are salmeterol’s beneficial effects on corticosteroid action in the
airways executed at the epithelial barrier?
Key words: airway epithelium, asthma, chronic obstructive
pulmonary disease, inflammation.
Abbreviations: COPD, chronic obstructive pulmonary
disease; FP, fluticasone propionate; ICS, Inhaled corticosteroids;
LABA, long-acting β2-agonists.
Asthma and chronic obstructive pulmonary disease
(COPD) are both chronic inflammatory respiratory
disorders with a worldwide increase in incidence.
Inhaled corticosteroids (ICS) are the cornerstone
of asthma treatment due to their broad anti-
inflammatory spectrum. They are effective in the
majority of asthma patients, although approximately
10% of asthma patients are insensitive to ICS and fail
to respond even when higher ICS doses are given.
Furthermore, ICS are relatively ineffective in sup-
pressing the inflammatory response in COPD,
although they effectively reduce COPD exacerbations
and have been suggested to reduce lung function
decline, at least in a subset of COPD patients, as
reported by the Groningen Leiden Universities
Corticosteroids in Obstructive Lung Disease study.1
Interestingly, combined treatment with long-acting
β2-agonists (LABA) has been shown to improve the
beneficial effects of ICS in respiratory disease. In
asthma, ICSare especially effectivewhenused in com-
binationwith LABA,2 and the addition of LABA ismore
effective in improving symptoms and lung function
and reducing the exacerbation numbers than dou-
bling the dose of ICS.3 Furthermore, several studies
have reported that ICS/LABA combination therapy is
more effective than ICS monotherapy in improving
symptoms and lung function in COPD. For example, a
3-month combination treatment with fluticasone/
salmeterol significantly reduced inflammation in
bronchial biopsies of patients with COPD, whereas no
significant effects of fluticasone monotherapy were
observed on airway inflammation.4
Themechanismunderlying the clinical observation
that combined treatment with LABA improves the
anti-inflammatory effects of ICS is not completely
clear. LABA have been proposed to enhance
corticosteroid-induced gene transcription by pro-
moting nuclear translocation of the glucocorticoid
receptor and its binding to glucocorticoid response
elements in anti-inflammatory genes, for example, in
airway epithelium.5 Additionally, LABA have been
suggested to enhance the anti-inflammatory effects
of ICS by extending the duration of action of ICS,2 as
the currently used ICS have a relatively short duration
of action. Although salmeterol and fluticasone
propionate (FP) have a tendency to form particle
agglomerations within the inhaler, salmeterol does
not likely extend the duration of FP actions by
pharmacodynamic and/or pharmacokinetic interac-
tions between the two drugs.6
In the current issue of Respirology, Haghi and
co-workers propose that salmeterol increases the
anti-inflammatory effects of ICS by increasing the
residence time of FP at the airway epithelium.7 Their
study shows for the first time that salmeterol prolongs
the transport of FP across the epithelial cell layer fol-
lowing co-deposition of salmeterol and fluticasone
particles on air–liquid interface cultured lung Calu-3
cells. Haghi et al. suggest that salmeterolmay do so by
improving epithelial barrier function.7 The deposition
of salmeterol alone or in combination with FP
resulted in increased transepithelial electrical resist-
ance during the time course of the experiment, which
was not the case for FP alone. This way, salmeterol
may increase the residence time of FP in the airways,
resulting in a prolonged anti-inflammatory action
of FP.
The findings of Haghi et al.7 are of particular inter-
est given the pro-inflammatory role of the airway epi-
thelial barrier in respiratory disease. The airway
epithelium forms the first barrier against environ-
mental insults, including cigarette smoke, pollutants,
allergens and pathogens. In addition to its physical
barrier function, airway epithelium plays a role in the
innate immune defence and is a source of pro-
inflammatory cytokines, especially when damaged.8
Abnormal epithelial damage and repair is thought to
contribute to the pathogenesis of asthma and COPD,8
and both cigarette smoke and aeroallergens impair
airway epithelial barrier function.8,9 Emerging evi-
dence suggests that, at least for asthma, these events
at the epithelial surface play a critical role in the
development of the disease.8 Reduced airway epithe-
lial barrier function is accompanied by the release of
pro-inflammatory mediators.8 Thus, by improving
epithelial barrier function, salmeterol may not only
enhance the suppressive effect of ICS on the produc-
tion of pro-inflammatory mediators,2 but also exert
anti-inflammatory effects itself by dampening the
release of epithelial pro-inflammatory mediators. In
addition to an increased inflammatory response,
the loss of epithelial barrier function may lead to
enhanced growth factor release and cross-talk
between the epithelium and underlying structural
cells, driving airway remodelling.8 Thus far, the com-
bined effect of ICS and LABA on airway remodelling
has not been studied extensively. However, Hoshino
and Ohtawa have recently shown that the combina-
tion of budesonide and formoterol is more effective
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than budesonide monotherapy in reducing airway
wall thickness and inflammation in asthma patients.10
Still, further studies are required to investigate
whether the effects of combined treatment on inflam-
mation can be separated from effects on airway wall
thickness. Furthermore, it remains to be established
whether formoterol exerts similar effects as
salmeterol on epithelial barrier function, andwhether
this would lead to similar effects on the transport of
budesonide as was the case for FP. The latter is of
specific interest, given the different chemical proper-
ties of FP and budesonide. Haghi and co-workers
mention that their results are in agreement with pre-
vious clinical findings, showing that FP is present for a
longer time in sputum than budesonide. However,
they did not compare the effects on FP and
budesonide in their assays. Budesonide is less
lipophilic than FP, leading to a faster dissolution rate
and a shorter retention time in the lining fluid of the
lungs. On the other hand, budesonide may permeate
slower through epithelial layers than FP, as
budesonide was shown to conjugate to fatty acids in
epithelial Calu-3 cells, resulting in prolonged intrac-
ellular retention.11 In addition to studying the effect of
LABA on the transepithelial transport of budesonide,
it will be of importance to assess the effects in a clini-
cally more relevant setting, using primary bronchial
epithelial cells. Given the abnormalities in airway epi-
thelial barrier function in asthma and possibly also
COPD, studying effects on diseased epithelial cells
will particularly be of interest. Nevertheless, Haghi
et al.7 refer to in vivo data that are in line with their
current findings, suggesting that the primary site of
beneficial effects of salmeterol is indeed the lung epi-
thelium. Together, the airway epithelial barrier seems
a plausible target for the beneficial effects of
salmeterol, decreasing epithelial permeability and
transepithelial transport, thus contributing to the
improvement of the anti-inflammatory actions of ICS.
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